drug
cetuximab
Marketedupdated 4mo agoby Eli Lilly Interamerica Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying cetuximab
- phase1Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
- phase2Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
- phase1A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
- phase2A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
- phase2Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- phase1A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
- phase1A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
- phase2KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
News(4)
- AstraZeneca scores in lung cancer; Sandoz inks a China dealA combination of AstraZeneca’s Tagrisso and Hutchmed’s Orpathys extended survival for some lung cancer patients. Elsewhere, MapLight floated the idea of partnering on its autism drug.biopharma_dive · 28d ago
- Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilarsThe initial batch of biosimilars includes copies of Amgen, Eli Lilly and GSK drugs that collectively generate billions of dollars in annual revenues.biospace · 28d ago
- Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhDMichael J. Pishvaian, MD, PhD discusses how biomarker-directed strategies, including HER2, CLDN18.2, and KRAS inhibition, are transforming GI cancer care.onclive · 4mo ago
- Fierce Biotech Fundraising Tracker '26: RegCell wrangles $66M; Encoded finagles $275M series FThe Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.fiercebiotech · 8mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that